CePA: Novel nanomedicine for alleviating MASH via mTOR repression

FHS
July 16, 2024
6:34 pm

Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases, primarily caused by metabolic disorders and systemic inflammatory responses.

AstraZeneca-Daiichi Sankyo’s gastric cancer therapy approved

AstraZeneca and Daiichi Sankyo’s Enhertu achieved a confirmed ORR of 28.8% and a median PFS of 5.7 months. Credit: Robert Way/Shutterstock. AstraZeneca and Daiichi Sankyo‘s

August 14, 2024

Introducing the Test post

I’m excited to share our latest free feature: The Psychedelic News Feed. This webpage aims to serve as a one-stop destination for the latest media

October 31, 2023

Biden Signs Executive Order to Boost Women’s Health Research

President Biden issued an executive order on Monday designed to increase the emphasis on women’s health research across the federal government. “In the early 1970s,

March 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.